Cargando…
Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
To address unresolved questions about drug safety and efficacy at the time of approval, the European Medicines Agency (EMA) may require that manufacturers conduct additional studies during the postmarketing period. As a growing proportion of new cancer drugs are approved on the basis of limited evid...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540185/ https://www.ncbi.nlm.nih.gov/pubmed/35662000 http://dx.doi.org/10.1002/cpt.2679 |